Quantum-Classical Hybrid Computing
By 2026, the "Quantum Advantage" is beginning to manifest in US drug discovery through Hybrid Computing models. While full-scale quantum computers are still evolving, informatics platforms are using quantum algorithms to solve specific, highly complex problems—such as "Protein Folding" and "Molecular Docking"—that are too computationally expensive for traditional supercomputers.
In these hybrid setups, a classical computer manages the overall workflow while offloading the most difficult mathematical simulations to a quantum processor. This has allowed US researchers to simulate the interaction of large, complex biologics (like monoclonal antibodies) with their targets in a fraction of the time it took in the early 2020s, opening the door to a new generation of sophisticated protein-based therapies.